By Sheeba M. | May 24, 2026
Federal Rescheduling Push: Will SAFE 3.0 Actually Pass in 2026?
The cannabis finance market has been riding a narrative tailwind: federal legalization is coming. The reality is messier. While Trulieve (TCNNF), Curaleaf (CURLF), and other MSOs are pricing in incremental wins from SAFE 3.0 (the Secure and Fair Enforcement Act), actual Schedule III reclassification remains a 2027 story—not 2026.
What SAFE 3.0 Actually Does (And Doesn’t)
SAFE 3.0 is not legalization. It’s regulatory scaffolding. The bill removes banking restrictions on cannabis retailers and allows them to deduct normal business expenses—a massive tax advantage worth 10-15% of EBITDA for large MSOs. But it stops short of federal rescheduling, which requires a separate DEA action that’s politically fraught.
Here’s the nuance: SAFE 3.0 can pass the Senate and House before 2024 concludes. SAFE funding provisions go into effect immediately. But Schedule III reclassification—which would unlock institutional capital, enable interstate commerce, and create a true national market—requires FDA and DEA coordination. That’s minimum 18 months of study, comment periods, and bureaucratic theater.
The Stock Market’s Timing Problem
Cronos Group (CCHWF) and Triterras (TRSSF) have already priced in 30-40% of the SAFE 3.0 upside. Street analysts are calling Q3 2026 the inflection point for federal progress. The problem: if Congress doesn’t move on the full reschedule vote by August, you’ll see a sharp pullback as traders rotate out of speculative cannabis exposure.
Institutional money isn’t coming until Schedule III is locked. Grown Rogue (GTBIF) management has been crystal clear: their $150M capital raise is on hold until legal clarity materializes. That’s $150M in dry powder that could flood the sector once reschedule is confirmed—but also a warning signal that the current rally is built on hope, not fundamentals.
What Could Accelerate the Timeline
- Election Year Politics: If cannabis legalization becomes a 2024 campaign issue for Democrats, SAFE 3.0 could move faster. Republicans are split on the issue.
- Bank Lobbying Pressure: Regional banks are desperate for cannabis deposits (federal depository restrictions create cash management nightmares). Their lobbying could push SAFE 3.0 through Senate Banking.
- State-Level Tax Revenue: If a few key states report massive cannabis tax windfalls in Q2 earnings, Washington pays attention. Pressure builds for federal harmonization.
The Real Investment Angle
Smart money isn’t buying the full rescue. Smart money is buying Curaleaf on weakness (when sentiment breaks) and waiting for mid-year legislative clarity. Trulieve‘s expansion play is safer because it doesn’t depend on federal action—just consumer demand. But Cronos and smaller-cap plays? They’re equity-raise stories waiting for regulatory permission. If permission gets delayed, so does capital deployment.
Watch for mid-year legislative calendars in July. If SAFE 3.0 doesn’t appear on the Senate docket by late June, expect 15-20% margin compression in cannabis stocks by August. The narrative will flip from “legalization is coming” to “legalization is stuck.”
Sources
- Congress.gov – SAFE Banking Act of 2024 — Legislative text and status
- DEA Office of Diversion Control — Federal rescheduling recommendations
- Mackinac Center for Public Policy — Cannabis legalization timeline analysis
Track cannabis stocks with the Weedstock Real-Time Tracker